




RealRate

PHARMACEUTICAL 2022

Lexicon Pharmaceuticals INC
Rank 220 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Lexicon Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lexicon Pharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 56% points. The greatest weakness of Lexicon Pharmaceuticals INC is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 32% points.

The company's Economic Capital Ratio, given in the ranking table, is 302%, being 27% points above the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	88,921
Cost of Goods Sold	0
Intangible Assets	44,543
Liabilities, Current	22,124
Liabilities, Non-Current	1,190
Other Assets	2,269
Other Compr. Net Income	-4.0
Other Expenses	802
Other Liabilities	0
Other Net Income	134
Other Revenues	298
Property and Equipment	1,176
Research and Development	55,046
Selling, General and Administrative Expense	32,342

Output Variable	Value in 1000 USD
Assets	136,909
Liabilities	23,314
Expenses	88,190
Revenues	298
Stockholders Equity	113,595
Net Income	-87,758
Comprehensive Net Income	-87,760
BaseVar	124,424
ECR before LimitedLiability	200%
Economic Capital Ratio	302%